How AI is rewriting the rules for medicine and biotech in Mass.

AI in pharma and medicine is being framed less as a faster way to discover drugs and more as a change in how scientists think about care. Flagship Pioneering COO Yvonne Hao told Axios’ Dan Primack that AI lets researchers run “all of the experiments in parallel,” accelerating discovery efforts that are already speeding progress on Moderna and Merck’s cancer vaccine work. Bayer event sponsor Yesmean Wahdan said AI’s biggest value is pushing scientists to challenge assumptions in areas like cell and gene therapy, cardiovascular health, and oncology. Clairity’s Connie Lehman highlighted a landmark FDA authorization for an AI model that predicts breast cancer risk from standard mammograms without adding routine work for radiologists.